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Dendritic cells (DC) are the most potent antigen-presenting cells that regulate immune responses. One of the mechanisms for
hepatitis C virus (HCV) persistence is the ability of HCV to suppress DC function. Direct HCV infection to blood DC has been
implicated for DC dysfunction. To clarify the susceptibility of each DC subset to HCV, we used pseudotype vesicular stomatitis virus
(VSV) coated with chimeric HCV envelope glycoproteins (E1 and E2). We demonstrate that pseudotype VSV enters myeloid DC
(MDC) but not plasmacytoid DC (PDC). The highest efficiency of pseudotype VSV entry to MDC was observed when MDC were
cultured with GM-CSF. Such efficiency decreased when MDC are matured with the treatment of IL-4, CpG oligodeoxynucleotide, or
CD40 ligand. Mannan inhibited pseudotype VSV entry to MDC, but Ca2+ chelators failed to do so. These results show that
pseudotype VSV possessing HCV-E1 and E2 enters immature MDC through the interaction with lectins in a Ca2+-independent
manner.
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Introduction persistence is the ability of HCV to escape from the hostHepatitis C virus (HCV), a single-stranded plus-sense
RNA virus belonging to the fraviviridae family (Miller
and Purcell, 1990), causes persistent infection in more
than 70% of infected patients. The most important feature
of HCV persistence is the potential for liver disease
progression from mild hepatitis to liver cirrhosis and
hepatocellular carcinoma (HCC) (Alter et al., 1989).
Chronic HCV infection is a serious health problem
because the total number of HCV-positive HCC patients
is growing worldwide. One of the mechanisms for HCV0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.03.038
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al., 1995). Cumulative studies show that functional im-
pairment of immunocompetent cells is found in patients
with chronic HCV infection (Corado et al., 1997; Wede-
meyer et al., 2002), suggesting that HCV has various
arms for suppressing the immune response.
Dendritic cells (DC) are the most potent antigen-
presenting cells (APC) that regulate various immune
responses (Banchereau and Steinman, 1998; Hart,
1997). Blood DC mainly consist of two subsets, that
is, myeloid and plasmacytoid DC (Liu, 2001). Myeloid
DC (MDC) are characterized by their potent immunosti-
mulatory properties for both primary and secondary T-
cell responses against virus. Plasmacytoid DC (PDC),
previously known as interferon (IFN)-producing cells,
produce a large amount of type I IFN upon virus
infection (Liu, 2001). However, some viruses such as
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cyte-derived DC (MoDC) or PDC and subsequently
inhibit their immunostimulatory functions (Grosjean et
al., 1997; Patterson et al., 2001; Schnorr et al., 1997).
Previous studies including our own have shown that
MoDC from patients with chronic HCV infection are
functionally impaired (Bain et al., 2001; Kanto et al.,
1999). In addition, our recent investigation revealed that
the function of both types of blood DC is suppressed as
well in HCV-infected patients (Kanto T. et al., unpub-
lished data). These results led us to hypothesize that
HCV infection to DC is one of the mechanism for DC
dysfunction in chronic hepatitis C patients.
The existence of the HCV genome in blood cells
including DC has been shown in several studies by means
of reverse transcription (RT)-PCR (Bain et al., 2001;
Lerat et al., 1996, 1998; Navas et al., 2002). The
detection of the positive strand of HCV-RNA does not
enable to define whether HCV enters cells or only adheres
to their surface. Alternatively, the negative strand of
HCV-RNA has been used as a surrogate marker of
HCV replication (Navas et al., 2002). Recently, Matsuura
et al. (2001) established the pseudotype vesicular stoma-
titis virus (VSV) having chimeric HCV E1 and E2 protein
as an envelope (VSV-E1E2). Because it has a green
fluorescent protein (GFP) reporter gene in its genome,
the infected cells can be viewed under fluorescence.
Using this system, we tried to clarify the susceptibility
of each DC to HCV. Consequently, we demonstrate that
MDC is susceptible to VSV-E1E2 but PDC is not.
Furthermore, we showed that the lectin-containing mole-
cules on MDC are critically involved in VSV-E1E2 entry.
Our study provides useful information for the exploration
of target molecules that efficiently block HCV entry to
DC.Fig. 1. Freshly isolated DC are not susceptible to VSV-E1E2. Freshly isolated CD3
pseudotype VSVs and the percentages of GFP+ cells were determined by flow cyResults
Immature MDC are susceptible to VSV-E1E2
We inoculated pseudotype VSV on various cells separat-
ed from PBMC or cord blood. Because no positive fluores-
cence was obtained from CD4 T cells, CD8 T cells, B cells,
NK cells, and fresh PDC inoculated with VSV DG-G which
is complemented with the VSV G protein, the susceptibility
of these cells to VSV-E1E2 could not be estimated. In
contrast, VSV DG-G entered fresh MDC, monocytes, and
CD34+ hematopoietic precursor cells on the day of separa-
tion, whereas VSV-E1E2 and VSV DG did not. Thus, fresh
MDC as well as DC precursors are not susceptible to VSV-
E1E2 (Fig. 1).
To examine the influence of differentiation or matura-
tion of DC on the susceptibility to the pseudotype VSV,
MDC were cultured in the presence of GM-CSF with or
without IL-4. Phenotypic analysis revealed that day 4
MDC cultured with GM-CSF and IL-4 had higher expres-
sion of CD1a and CD86 than those cultured with GM-CSF
only (Fig. 2), showing the role of IL-4 in DC maturation.
No significant difference was observed in the expression of
CD11c, CD40, CD80, CD83, and HLA-DR between these
MDC (Fig. 2). On day 4 of culture in the presence of IL-3,
PDC showed higher expressions of CD40, CD80, CD83,
and CD86 when compared to the day of separation (data
not shown).
After the inoculation with VSV DG-G, positive signals
were obtained from day 4 MDC and day 4 PDC,
regardless of the difference of cytokines used (Figs. 3A
and B). No significant signals were detected from day 4
MDC and day 4 PDC inoculated with VSV DG. With
respect to VSV-E1E2, GFP+ cells were observed in day 4
MDC but not in day 4 PDC (Figs. 3A and B). In4+ hematopoietic precursor cells, monocytes, or MDC were inoculated with
tometry. Representative results from three experiments are shown.
Fig. 2. Phenotypes of MDC cultured with GM-CSF or GM-CSF and IL-4. Flow cytometric analyses of surface molecules on day 4 MDC, obtained from
healthy volunteers, cultured with GM-CSF (A) or with GM-CSF and IL-4 (B). Representative results from three subjects are shown. Open histograms represent
the results with isotype Ab and filled ones represent those with relevant Abs. Fluorescence intensity is shown in the x-axis and the number of cells is shown in
the y-axis.
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percentage of GFP+ cells was observed in day 4 MDC
cultured with only GM-CSF than those with GM-CSF
and IL-4 (Fig. 3B).
To confirm the reliability of the pseudotype VSV
system in the assessment of E1E2-mediated virus entry,
we quantified HCV-RNA in day 4 cultured MDC or PDC
after inoculation of a window-period serum from a
hepatitis C patient. Among the cells examined, the highest
HCV RNA titer was detected in day 4 MDC cultured
with GM-CSF (Fig. 3C), which was compatible with the
results obtained with the pseudotype VSV. In contrast
with the results of VSV-E1E2 inoculation, low-level HCV
RNA were detected by quantitative RT-PCR in PDC
inoculated with authentic HCV (Fig. 3C). To further
investigate whether HCV replicates in each DC subset
after HCV inoculation, we performed strand-specific RT-
PCR for the detection of negative-strand HCV-RNA as a
surrogate marker of HCV replication. Positive strand of
HCV-RNA was detected both in MDC cultured with GM-
CSF and PDC with IL-3, whereas negative strand was
detected in GM-CSF-MDC but not in IL-3-PDC (Fig.
3D). These results suggest that HCV replicates in GM-
CSF-MDC but not in IL-3-PDC. Therefore, the data with
the pseudotype VSV system correctly reflect the suscep-
tibility of cells to authentic HCV.
Maturation stimuli protect MDC from VSV-E1E2
Based on the findings described above, we hypothesized
that the more MDC mature, the less susceptible they are to
VSV-E1E2. To find the substances protecting DC from
HCV infection, we treated MDC with various maturation
factors for the inoculation study. In MDC cultured with GM-
CSF, the addition of IL-4, CpG oligodeoxynucleotide
(ODN) 2006, or CD40 ligand (CD 40L) to the culture
significantly reduced the percentage of GFP+ cells withVSV-E1E2 without influencing their susceptibility to VSV
DG-G (Fig. 4). On the other hand, IFN-a, polyI:C, TNF-a,
and lipopolysaccharide (LPS) reduced the percentage of
GFP+ cells with both VSV-E1E2 and VSV DG-G (Fig. 4).
Phenotypic analysis revealed that IL-4 up-regulated the
expression of CD1a and CD86 on MDC cultured with
GM-CSF (Fig. 2). CpG ODN or CD40L also up-regulated
the expression of CD1a, CD83, and CD86 on MDC cultured
with GM-CSF (data not shown). Therefore, immature DC
lose their susceptibility to VSV-E1E2 as they develop to be
more mature state.
Lectin on DC is involved in VSV-E1E2 entry to DC
The C-type lectins expressed on DC are reported to
interact with various viruses as well as microbial agents
(Geijtenbeek et al., 2000; Tailleux et al., 2003). These
studies led us to consider the involvement of lectins in
VSV-E1E2 entry to DC. Thus, we first used mannan to
examine whether it inhibits VSV-E1E2 entry to MDC.
The pretreatment of MDC with mannan reduced the
percentage of GFP+ cells with VSV-E1E2 in a dose-
dependent manner without having any impact on VSV
DG-G entry (Fig. 5A). Such an inhibitory effect of
mannan was confirmed with MDC inoculated with au-
thentic HCV (data not shown). A D-mannose-specific
lectin, methyl a-D-mannopyranoside (Kaku et al., 1991),
also inhibited VSV-E1E2 entry to MDC in a dose-
dependent fashion at concentrations from 10 to 40 Ag/
ml (data not shown). In contrast, galactose had no effect
on the infection with either VSV-E1E2 or VSV DG-G in
MDC (Fig. 5A). Interestingly, EDTA did not reduce the
infectivity of VSV-E1E2, whereas it completely abolished
that of VSV DG-G (Fig. 5A). These data demonstrate that
mannose-type carbohydrate is involved in the interaction
of DC with VSV-E1E2 in a Ca2+-independent manner.
The treatment of MDC with antihuman DC-SIGN Ab,
Fig. 3. Myeloid DC cultured with GM-CSF are susceptible to VSV-E1E2 or authentic HCV from patient serum. Day 4 MDC cultured with GM-CSF or with
GM-CSF and IL-4 or day 4 PDC cultured with IL-3 were inoculated with VSV DG, VSV DG-G, or VSV-E1E2. They were viewed under fluorescence
microscopy (A) and the percentages of GFP+ cells were analyzed by flow cytometric analysis (B). The results of fluorescence microscopy are the representative
ones from three subjects. The results of flow cytometric analysis are expressed as the mean + SD from three representative experiments. *P < 0.001 vs. VSV-
E1E2-inoculated day 4 MDC cultured with GM-CSF. (C) Quantitative analysis of HCV RNA in DC inoculated with HCV-positive patient serum was
performed as described in Materials and method. D4-GM or D4-GM/4 represents MDC cultured with GM-CSF or GM-CSF and IL-4 for 4 days. D4-IL 3
represents PDC cultured with IL-3 for 4 days. The results are expressed as the mean + SD of triplicate wells from three representative experiments. (D) The
detection of positive and negative strand of HCV-RNA in DC inoculated with HCV-positive patient serum. Strand-specific RT-PCR was performed with
samples from MDC, PDC, and patient serum used as inoculum, as described in Materials and method. D4-GM and D4-IL 3 represent as the same as above.
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ICAM-3 (Wu et al., 2002), did not inhibit the entry of
either VSV-E1E2 or VSV DG-G (Fig. 5B). To see
whether the expression of DC-SIGN on MDC parallels
their susceptibility to VSV-E1E2, we compared the ex-
pression of DC-SIGN between MDC cultured with GM-
CSF and those with a combination of GM-CSF and IL-4.
The expression of DC-SIGN was higher on MDC cul-
tured with GM-CSF and IL-4 than on those with GM-CSF (Fig. 5C), which is contrary to their susceptibility to
VSV-E1E2. These results show that DC-SIGN is less
likely to be involved in the VSV-E1E2 entry to MDC.
Human hepatoblastoma cell line, HepG2, is one of the
most sensitive cells to pseudotype VSV (Matsuura et al.,
2001). To compare the machinery of VSV-E1E2 entry
between MDC and HepG2, we inoculated it to mannan-
treated HepG2. In contrast to MDC, mannan did not
inhibit the VSV-E1E2 entry to HepG2 (Fig. 5D), suggest-
Fig. 4. IL-4, CpG ODN, or CD40L protects MDC from VSV-E1E2. Various immunomodulators were added to MDC cultured with GM-CSF, and the ratio of
infection was determined between the cells treated with or without the reagents. IFN-a (100 U/ml), IFN-g (100 U/ml), IL-3 (50 ng/ml), or IL-4 (10 ng/ml) was
added on the day of MDC separation. CpG ODN 2006 (10 AM), CD40L (1 Ag/ml), polyI:C (50 Ag/ml), TNFa (20 ng/ml), or LPS (10 Ag/ml) was added to
MDC 24 hrs before the pseudovirus inoculation. Representative results are shown from three independent experiments.
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differ between HepG2 and MDC. Furthermore, it also
shows that mannan affects the molecules on MDC but not
those on VSV-E1E2.Discussion
Using the pseudotype VSV system, we have demonstrat-
ed that each DC subset has distinct susceptibility to HCV.
First, VSV-E1E2 enters MDC but not PDC, which is in
sharp contrast with PDC susceptibility to HIV (Patterson et
al., 2001). Second, MDC cultured with GM-CSF are more
susceptible to VSV-E1E2 than freshly prepared MDC or
those cultured with GM-CSF and IL-4, showing that HCV
targets immature MDC. Third, certain molecules containing
the lectin domain on MDC are involved in the interaction
with VSV-E1E2.
One of the suggested mechanisms of persistent HCV
infection is the functional suppression of immunocompetent
cells, including NK cells, T cells, and DC (Bain et al., 2001;
Corado et al., 1997; Kanto et al., 1999; Wedemeyer et al.,
2002). The possibility being raised for such immunological
impairment is that HCV directly infects these blood cells. To
elucidate this issue, investigators have used RT-PCR to
examine whether the HCV genome is detectable or not in
blood cells recovered from HCV-infected patients (Bain et
al., 2001; Lerat et al., 1996, 1998). However, the existence
of HCV-RNA does not enable to define whether HCVenters
cells or only adheres to their surface. Instead of qualitative
RT-PCR, we used the pseudotype VSV system to study the
HCV E1E2-mediated virus entry to each DC subset. The
pseudotype VSV system is a valid model for investigating
the early steps of HCV infection, that is, viral attachment,
receptor binding, and membrane fusion. Also, it enables usto estimate the efficiency of HCV E1E2-mediated virus
entry to target cells. However, there are several limitations
in this system. First, the positive results with pseudotype
VSV do not indicate the replicative ability of HCV in the
relevant cells. Because pseudotype VSV is constructed from
VSV genome, their replication capacity is not exactly the
same as HCV. Second, the evaluation of pseudotype VSV
entry is possible only in cells that permit VSV replication. In
other words, it cannot be used to determine the entry of
VSV-E1E2 in the cells that suppress VSV replication. In this
study, we could not evaluate the susceptibility of T, B, NK
cells or fresh PDC to VSV-E1E2.
Alternatively, we performed an inoculation experiment
with authentic HCV particle to confirm the reliability of the
pseudotype VSV system. Quantitative RT-PCR assay
showed that the highest titer of HCV-RNA was detected in
MDC cultured with GM-CSF; however, low titer of HCV-
RNAwas detected in PDC. We hypothesized that the reason
such discrepancy occurs between two assays is that RT-PCR
amplified HCV genome from HCV attached to the surface
of PDC. Strand-specific RT-PCR showed that negative
strand of HCV-RNA, a surrogate marker of HCV replica-
tion, was detected in MDC cultured with GM-CSF but not
in PDC. These results indicate that HCV enters and repli-
cates in MDC but not in PDC, which are well correlated
with those of pseudotype VSV entry.
The Th1 response is thought to be needed to eradicate
HCV from hosts (Gerlach et al., 1999). Myeloid DC
potentially activate CD4+T cells to support Th1 differen-
tiation (Liu, 2001). We found that MDC from HCV-
infected patients are less able to induce the Th1 response
than the normal counterpart (Kanto T., unpublished data).
It has been reported that MoDC expressing HCV protein
were impaired in the stimulation of allogeneic T cells and
IL-12 production, indicating an inhibitory capacity of HCV
Fig. 5. Mannan inhibits VSV-E1E2 entry to MDC, but not to HepG2. Various concentrations of mannan, galactose, or 5 mM EDTAwere added to day 4 MDC
cultured with GM-CSF before the pseudotype VSV inoculation. Alternatively, day 4 MDC were treated with 2, 10, or 50 Ag/ml antihuman DC-SIGN Ab or 10
Ag/ml isotype IgG2B for 30 min before the pseudotype VSV inoculation. HepG2 was treated with 5 Ag/ml mannan before the addition of pseudotype VSV. The
ratio of infection with pseudotype VSV in MDC (A, B) or HepG2 (D) was determined as described in Materials and method. Representative results are shown
from three independent experiments. (C) Flow cytometric analyses were done for DC-SIGN expression on day 4 MDC cultured with GM-CSF (a) or with GM-
CSF and IL-4 (b) generated from a healthy volunteer. Representative results from three subjects are shown. Open histograms represent the results with isotype
Ab and filled ones represent those with anti-DC-SIGN Abs. Fluorescence intensity is shown in the x-axis and the number of cells is shown in the y-axis.
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suggest that direct HCV infection to myeloid DC suppress
their function. Thus, the protection of DC from HCV
infection is a rational approach to improve DC-mediated
anti-HCV immune response. In the present study, we
demonstrate that some of the maturation stimuli are capa-
ble of protecting DC from VSV-E1E2 entry. However,
MoDC from HCV-infected patients are reported to be
resistant to maturation stimuli, such as TNF-a (Auffer-
mann-Gretzinger et al., 2001). Thus, further investigationis necessary to determine the effective modulation that
allows MDC to mature in HCV infection. As shown in this
study, CpG ODN or CD40L stimulated MDC to mature
and become less susceptible to VSV-E1E2. The potent
ability of CpG ODN to stimulate a DC-inducing Th1
response has been demonstrated in vivo tumor treatment
models (Heckelsmiller et al., 2002). Therefore, CpG ODN
are promising as a DC adjuvant in HCV-infected patients
that potentially leads to MDC maturation as well as
boosting Th1 response.
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responsible for HCV entry to protect DC. Previously,
tetraspanin CD81 has drawn much attention as a presumed
HCV receptor due to its high affinity to HCV-E2 (Pileri et
al., 1998). However, its involvement in VSV-E1E2 entry is
unlikely because the CD81 is equally expressed on both
MDC and PDC but is lacking on the VSV-E1E2-sensitive
cell line HepG2 (Flint et al., 1999). In this study, we showed
some of the characteristics of the molecules on DC involved
in VSV-E1E2 entry. They are myeloid-lineage specific,
inducible by GM-CSF, down-regulatable by IL-4 or other
maturation stimuli. In addition, they possess some lectin
domain, as evidenced by the inhibition of VSV-E1E2 as
well as authentic HCV entry with mannan. These results
raised the possibility that such molecules are categorized as
members of C-type lectins, such as DC-SIGN, mannose
receptor (MR), Langerin, DEC205, BDCA2, or asialogly-
coprotein receptor. (Figdor et al., 2002) Recently, two
independent studies have demonstrated that HCV E1 and
E2 glycoproteins efficiently bind to DC-SIGN (Lozach et
al., 2003; Pohlmann et al., 2003). However, the involvement
of DC-SIGN in VSV-E1E2 entry is less likely because its
expression on MDC did not parallel the susceptibility to
VSV-E1E2. In addition, the treatment with anti-DC-SIGN
Ab did not inhibit VSV-E1E2 entry. Furthermore, the
treatment with EDTA failed to block VSV-E1E2 entry to
MDC, showing that the VSV-E1E2 entry occurs in a Ca2+-
independent manner. It is still obscure in which step lectins
are involved in VSV-E1E2 entry to MDC. From an analogy
with the interaction of HIV with DC-SIGN (Geijtenbeek et
al., 2000), it is conceivable that lectins are essential for HCV
attachment to MDC. Nevertheless, the possibility remains
that HCV entry receptors or co-receptors, which may be
other than lectins, exist on MDC. With the aid of the
pseudotype VSV system, exploration has been underway
to identify the molecules on MDC that are critically in-
volved in HCV infection.Materials and method
Reagents
Recombinant human IL-4 and GM-CSF were purchased
from PeproTech (London, UK). Recombinant human solu-
ble CD40L, human TNF-a and IL-3, and mouse monoclo-
nal antihuman DC-SIGN (CD209/DC-SIGN1) Ab (12507)
were from R & D Systems (Minneapolis, MN). LPS,
polyI:C, mannan, galactose, and methyl a-D-mannnopyra-
noside were from Sigma (St. Louis, MO). Recombinant
human IFN-g was from Strathman Biotech GmbH (Ham-
burg, Germany). Human lymphoblastoid IFN-a was pro-
vided by Sumitomo Pharmaceuticals (Osaka, Japan).
Unmethylated CpG ODN 2006 (Krug et al., 2001) was
synthesized at and purchased from Sigma Genosys (Hok-
kaido, Japan). Isotype IgG (mouse IgG2B) for the blockingexperiments was kindly provided from the JT laboratory
(Osaka, Japan).
Separation of DC precursors and other cells from PBMC
After informed consent had been obtained from healthy
volunteers, buffy coats were isolated from venous blood
drawn from them at the Osaka Red Cross Blood Center
(Osaka, Japan). PBMC were collected from buffy coats by
Ficoll–Hypaque density-gradient centrifugation. B cells,
MDC, and PDC were magnetically isolated by using
CD19 microbeads, BDCA-1, or BDCA-4 DC isolation kits
from Miltenyi Biotec (Bergish-Gladbach, Germany), respec-
tively. BDCA-1+ and BDCA-4+ cells are phenotypically
compatible with MDC and PDC, respectively (Dzionek et
al., 2000). CD4, CD8 T cells, and NK cells were separated
from PBMC by using the relevant Stem-Sep kits (Stem Cell
Technologies Inc, Vancouver, BC). CD34+ hematopoietic
precursor cells were isolated from cord blood mononuclear
cells by using CD34-microbeads from Miltenyi. The purity
of all isolated cells was more than 90% as determined by
FACS Caliber (Becton Dickinson Immunocytometry Sys-
tems, San Jose, CA).
Culture of DC
Isolated MDC were cultured for 4 days in IMDM
(GIBCO Laboratories, Grand Island, NY) supplemented
with 10% FCS, 50 IU/ml penicillin, 50 Ag/ml streptomycin,
2 mM L-glutamine, 10 mM Hepes buffer, and 10 AM
nonessential amino acid (Complete medium, CM) contain-
ing 50 ng/ml GM-CSF with or without 10 ng/ml IL-4. PDC
were cultured for 4 days in CM in the presence of 50 ng/ml
of IL-3.
Flow cytometry
The expression of surface molecules on DC was ana-
lyzed by FACS Caliber (Becton Dickinson). For the stain-
ing, DC were stored with specific Abs or isotype Abs for 30
min at 4 jC in PBS containing 2% of BSA and 0.1% of
sodium azide. The following FITC-, PE-, PerCP-, or PC5-
conjugated antihuman mAbs were used: CD1a (NA1/34;
DAKO, Glostrup, Denmark), CD11c (KB90; DAKO),
CD14 (M5E2; Becton Dickinson), CD40 (5C3; BD Phar-
mingen, San Diego, CA), CD80 (L307.4; BD Pharmingen),
CD83 (HB15a; Immunotech, Marseille, France), CD86
(IT2.2; B70/B7-2, BD Pharmingen), CDw123 (7G3; IL-3
receptora chain, BD Pharmingen), DC-SIGN (120507; R &
D Systems), and HLA-DR (L243; Becton Dickinson).
Assessment of pseudotype VSV entry into cells
To find which blood cells are susceptible to HCV
infection, we used pseudotype VSV possessing chimeric
HCV E1 and E2 protein which was generated as described
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consists of recombinant VSV in which glycoprotein (G)
gene is replaced with a reporter gene encoding GFP.
As an envelope, it possesses chimeric HCV E1 and E2
proteins (VSV-E1E2). The viruses were purified by centri-
fugation at 25000 rpm for 2 h at 4 jC in SW28 rotor
(Beckman Coulter Inc., Fullerton, CA) through 20% (v/w)
and 60% (v/w) discontinuous sucrose gradient and were
stored at 80 jC. To determine RNA copy numbers in the
viral samples, TaqMan EZ RT-PCR kit (PE Applied Bio-
systems, Foster City, CA) was used. We used forward and
reverse primers (5V-cattattatcattaaaaggctc-3V and 5V-gata-
caaggtcaaatattccg-3V) that amplify a 323-bp segment of the
pseudotyped VSV RNA and also used a dual fluorophore-
labeled probe 5V-(6-carboxy-fluorescein)-atccagtggaa-
tacccggcagattac-(6-carboxy-tetramethyl-rhodamine)-3V. The
sequence detector (ABI Prism 7000, PE Applied Biosys-
tems) allows measurement of the amplified products in
indirect proportion to the increase in fluorescence emission
continuously during the PCR amplification. The copy
numbers in samples were determined based on the standard
curve drawn by a known amount of in vitro synthesized
pseudotyped VSV RNA. Because VSV efficiently replicates
in a wide range of mammalian cells, we are able to
determine the cells exhibiting susceptibility to pseudotype
VSV by the expression of GFP. We used VSV DG which
has no envelope protein as a negative control. Similarly,
VSV DG-G was used as a positive control which is
complemented with the VSV G protein. Various separated
blood cells were prepared in CM at 5  104 cells/well on
96-well culture plates. Next, they were inoculated with the
pseudotype viruses, VSV-E1E2 (1  1012 RNA copies/
well), VSV DG (1  1012 RNA copies/well), or VSV DG-G
(1  1011 RNA copies/well) and incubated for 16 h at 37
jC. The infected cells (GFP+ cells) were observed under
fluorescence microscopy, and their positive percentages
were determined by FACS analysis. The net percentage of
infected cells was expressed as % infection = (% of GFP+
cells with VSV-E1E2 or VSV DG-G)  (% of GFP+ cells
with VSV DG).
To find the substances which potentially protect DC from
HCV infection, we examined IFNa, IFNg, IL-3, IL-4, CpG
ODN 2006, CD40L, polyI:C, TNFa, or LPS for this
purpose. The appropriate concentrations of these reagents
were determined in a separate series of experiments. IFNa,
IFNg, IL-3, or IL-4 was added to DC on the day of
separation. CpG ODN 2006, CD40L, polyI:C, TNFa, or
LPS was added to DC 24 h before the inoculation of
pseudovirus. To compare the inhibitory effect of reagents
in VSV-E1E2 entry into cells, we determined the ratio of
infection of cells with and without treatment.
DC express various molecules containing the lectin do-
main, some of which are reported to be essential for the
attachment to virus (Figdor et al., 2002). To examine whether
lectin-containing molecules on DC are involved in HCV
infection, we tested mannan, methyl a-D-mannopyranoside,and galactose for the inhibition of VSV-E1E2 entry. Day 4
MDC cultured with GM-CSFwere preincubated with various
concentrations of mannan, methyl a-D-mannopyranoside, or
galactose at 37 jC for 180 min and inoculated with the
pseudotype VSV. We also treated DC with EDTA (5 mM),
monoclonal antihuman DC-SIGN Ab (50, 10, or 2 Ag/ml), or
isotype IgG2B before the pseudotype VSV inoculation. To
compare DC with hepatoblastoma cell line, HepG2, we
treated HepG2 with mannan before the inoculation.
Quantitative analysis of HCV RNA in cells inoculated with
HCV particles from patient serum
To test the susceptibility of each DC subset to authentic
HCV, we quantified HCV RNA in cells that had been
inoculated with patient serum by means of real-time PCR.
We used the commercial HCV seroconversion panel as an
inoculum, which contains high HCV RNA titer (1  105
copies/Al) and no anti-HCV antibody (BioClinical Partners,
Inc, USA). We added 3 Al/well of inoculum to DC on 96-
well plates and incubated them at 37 jC for 24 h. DC were
harvested and washed three times with IMDM supple-
mented with 1% FCS and then total RNA was extracted
from DC using RNeasy Mini Kit (QIAGEN, Germany). To
measure HCV RNA, TaqMan EZ RT-PCR kit (PE Applied
Biosystems) was used. We used forward and reverse primers
[5V-cgggagagccatagtgg-3V (positions 130–146) and 5V-agtac-
cacaaggcctttcg-3V (positions to 272 to 290)] that amplify a
161-bp segment of the 5V noncoding region of HCV RNA
and also used a dual fluorophore-labeled probe [5V-(6-
carboxy-fluorescein)-ctgcggaaccggtgagtacac (positions
148–168)- (6-carboxy-tetramethyl-rhodamine) -3V]. The se-
quence detector (ABI Prism 7000) allows measurement of
the amplified products in indirect proportion to the increase
in fluorescence emission continuously during the PCR
amplification. The copy number in the samples was deter-
mined based on the standard curve drawn by a known
amount of in vitro synthesized HCV RNA.
The strand-specific RT-PCR assay for HCV-RNA in cells
inoculated with authentic HCV particles
To detect negative-strand HCV-RNA that is indicative of
RNA replication, we performed the strand-specific RT-PCR
assay referring to the methods described by Navas et al.
(2002) with some modifications. We used the same batch of
HCV seroconversion panel as an inoculum as described in
the above section. We added 3 Al/well of inoculum to DC on
96-well plates and incubated them at 37 jC for 24 h. After
the washing of DC for three times, total RNAwas extracted
from DC as the same way as we did in quantitative RT-PCR.
As a control for the detection of HCV-RNA, 9 Al of
inoculum was used. We used sense and anti-sense primers
[5V-cactcccctgtgaggaactactgtc-3V (positions 38–62) and 5V-
atggtgcacggtctacgagacctcc-3V (positions 319–343) that am-
plify a 306-bp segment of the 5V noncoding region of HCV
A. Kaimori et al. / Virology 324 (2004) 74–8382genome. Ten microliters of purified RNA was used for
reverse transcription (RT) with 10 Al of RT reaction mixture
containing the thermostable recombinant Thermus thermo-
philus (rTth) enzyme (PE Applied Biosystems). Synthesis of
cDNA was carried out with strand-specific primers, sense
primer was used to obtain negative-strand RNA, and anti-
sense primer was used to obtain positive-strand RNA,
respectively. Reverse transcription was carried out at 70
jC for 15 min. Subsequently, the same primers were used in
reverse order in the PCR rounds. Thirty-five cycles of PCR
(94 jC for 45 s, 60 jC for 45 s, 72 jC for 45 s) followed by
7 min of extension at 72 jC were carried out on GeneAmp
PCR System (PE Applied Biosystems). One-fifth of the
PCR products was subjected to electrophoresis on 2%
agarose gel and stained with ethidium bromide for obser-
vation under UV light. The expected molecular size of PCR
products derived from target HCV RNA was 306 bp.
Statistical analysis
The paired t test was used to test the significance of the
pseudotype VSV entry to MDC. Statistical analyses were
performed with the Statview version 4.5 software (Abacus
Concepts, Berkeley, CA). A P value of less than 0.05 was
considered statistically significant.Acknowledgment
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